8,473 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 8,473 shares of the company's stock, valued at approximately $588,000.

Several other hedge funds have also recently modified their holdings of the stock. Cohen Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 135.1% in the first quarter. Cohen Capital Management Inc. now owns 6,212 shares of the company's stock valued at $431,000 after buying an additional 3,570 shares in the last quarter. Fortress Financial Solutions LLC purchased a new position in shares of Novo Nordisk A/S in the first quarter valued at $251,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the first quarter valued at $731,000. Bleakley Financial Group LLC boosted its stake in shares of Novo Nordisk A/S by 0.9% during the first quarter. Bleakley Financial Group LLC now owns 70,718 shares of the company's stock valued at $4,911,000 after acquiring an additional 625 shares during the last quarter. Finally, LRI Investments LLC boosted its stake in shares of Novo Nordisk A/S by 3.7% during the first quarter. LRI Investments LLC now owns 13,548 shares of the company's stock valued at $941,000 after acquiring an additional 488 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 2.3%

NVO stock traded down $1.62 during midday trading on Tuesday, hitting $67.32. 7,237,088 shares of the company's stock were exchanged, compared to its average volume of 7,328,326. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.49. The firm has a 50 day moving average price of $70.35 and a 200-day moving average price of $74.78. The stock has a market capitalization of $300.59 billion, a price-to-earnings ratio of 19.92, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion during the quarter. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on NVO shares. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.